All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2017-04-28.
From the record
Champions Oncology, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2017-04-28) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+14.4% a year over 9 filed years; profitable in 4 of 9.
From the record
Champions Oncology, Inc.'s 9 filed years say what it did: revenue went from $20 million in fiscal 2018 to $59 million in fiscal 2026, up 14.4% a year; it rose in 7 of 8 years; the deepest fall was 7% from fiscal 2023 to fiscal 2024; net income was positive in 4 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Champions Oncology, Inc.'s shareholder treatment is put at 8.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 12% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -30%: lost 30¢ per shareholder dollar. Leverage 85%: owes 85¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2026-04-30, Champions Oncology, Inc. lost about 30 cents for every dollar of shareholders' money, and gross profitability: its products earned about 106 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 85 cents per dollar of assets, and net share issuance: its share count shrank 3.0% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 38% of 102 in its family; net margin -2%.
From the record
Champions Oncology, Inc.'s standing among 102 graded names in its industry family: revenue of $59 million in fiscal 2026 ranks in the top 39% by size; a net margin of -2% ranks in the top 22%; revenue growth of 3.3% a year over the last 3 filed years ranks in the bottom 49% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 40% of 110 in its family for leadership; chief executive since 2026.
From the record
Champions Oncology, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Brainin, Robert Lawrence (CEO, as filed), filing under that title since 2026-01-30, 9 months (bottom 11% of its family); the 6 officers and directors filing in the last fifteen months have been on the record a median of 14.5 years (top 1%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 6 people in charge now (top 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 37% of 92 in its family for room to expand.
From the record
Champions Oncology, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $5 million against no long-term debt tagged leaves 18.1% of its assets as net cash, bottom 33% of its family; cash from operations less capital spending is -8.5% of revenue (top 21%); a gross margin of 48% (bottom 24%); research spending of 15.3% of revenue (bottom 12%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 39% of 100 in its family for growth drivers.
From the record
Champions Oncology, Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew 3.3% a year over the last three filed years against 14.4% over all 9, slowing (bottom 45% of its family); the newest year grew 4.4% (bottom 42%); research spending grew -7.7% a year (bottom 29%); capital spending grew -41.9% a year (bottom 41%) (its annual reports). Champions Oncology, Inc. reported 3 product lines in fiscal 2026: Pharmacology Services at $57 million (96%), Product and Service Other at $2 million (3%), Translational Oncology Solutions TOS License Revenue at $764 thousand (1%); 1 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 47% of 72 in its family for expectations against reality.
From the record
Champions Oncology, Inc.'s newest year against its own record: revenue of $59 million in fiscal 2026 came in 1.5% above the $59 million its prior three years' pace pointed to (top 50% of its family); net income of $1 million against a prior three-year average of $3 million (top 27%); a net margin of -2% against -5.4% before (bottom 37%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made